Parexel’s BioPharm Unit to aid smaller R&D firms
pharmafile | July 25, 2012 | News story | Research and Development |Â Â Parexel, R&D, biotechÂ
Parexel has launched the Parexel BioPharm Unit – a new division focused on the needs of small and mid-sized biopharma companies.
Recent data indicates that small and mid-sized companies are the engine of the biopharmaceutical industry, with 81% of ongoing development programmes originating from sponsors outside of the top 25 pharma firms.
The Parexel BioPharm Unit will provide precise expertise, global infrastructure, operational excellence and turn-key technologies needed to help small biopharmaceutical companies advance their drugs through the development cycle.
Parexel has designed this new delivery model to provide a high level of attention and service. The goal is to provide a tailored solution that results in accelerated development timelines, reduced cost and a high level of quality.
“Small and mid-sized biopharmaceutical companies are truly the genesis of innovation and have been an important part of Parexel’s client base for more than 30 years,” said Ubavka DeNoble, vice president of BioPharm Services.
“The creation of the Parexel BioPharm Unit is especially important for small pharma and biotech sponsors that have needs that are meaningfully different from large pharma sponsors.
“The breadth and depth of our expertise gives us the ability to create customised solutions that are designed to meet the particular needs of each client – whether the company is a small research venture, a growing mid-sized business, or a global enterprise.”
The Parexel BioPharm Unit provides a senior management leader and dedicated team offering ongoing, frequent communication and proactive solutions. The BioPharm Unit will help firms accelerate patient recruitment, increase the speed of study start-up, shorten time to database lock, and improve overall efficiency for meeting critical development milestones.
Related Content
Cellbyte raises $2.75m to fund pharma drug launch platform
Cellbyte has announced that it has raised $2.75m in seed funding for the streamlining of …
Lilly opens fourth US Gateway Labs site
Eli Lilly has opened its newest Lilly Gateway Labs (LGL) site in San Diego, California, …
LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …
